Your browser doesn't support javascript.
loading
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Gyawali, B; Shimokata, T; Ando, M; Honda, K; Ando, Y.
Afiliación
  • Gyawali B; Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya.
  • Shimokata T; Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya.
  • Ando M; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
  • Honda K; Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya.
  • Ando Y; Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya.
Ann Oncol ; 28(2): 246-253, 2017 02 01.
Article en En | MEDLINE | ID: mdl-27771613

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Compuestos de Fenilurea / Niacinamida / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Compuestos de Fenilurea / Niacinamida / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
...